For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic ...
Kasi: The overall response rate and the reported side effects don’t necessarily encompass the tangible impact that we're ...
The 5-year relative pancreatic cancer survival rate in the United States is 12.5%. However, survival rates vary greatly based on the stage of the cancer at diagnosis. The statistic cited above comes ...